98 CHAPTER 2.2 Table SI1.3. Continued. STOPP Condition Clarity rating n=80 B10 unless clear intolerance of, or lack of efficacy with, other classes of antihypertensives 75% D3 with a history of prostatism or previous urinary retention 75% D4 with current or recent significant hyponatraemia i.e. serum Na+ < 130 mmol/l 75% G1 as monotherapy for COPD 75% J1 with type 2 diabetes mellitus 75% C4 as secondary stroke prevention, unless the patient has a coronary stent(s) inserted in the previous 12 months or concurrent acute coronary syndrome or has a high grade symptomatic carotid arterial stenosis 83% D12 as first-line treatment, 83% E1 if eGFR < 30 ml/min/1.73m2 83% J4 with a history of breast cancer or venous thromboembolism 83% K3 with persistent postural hypotension i.e. recurrent drop in systolic blood pressure ≥ 20mmHg 83% B3 in combination with verapamil or diltiazem 92% C1 [Long-term aspirin at doses greater than 160mg per day] 92% F1 with Parkinsonism 92% G4 with acute or chronic respiratory failure i.e. pO2 < 8.0 kPa ± pCO2 > 6.5 kPa 92% H9 in patients with a current or recent history of upper gastrointestinal disease i.e. dysphagia, oesophagitis, gastritis, duodenitis, or peptic ulcer disease, or upper gastrointestinal bleeding 92% C2 with a past history of peptic ulcer disease without concomitant PPI 100% C7 in any circumstances 100% D6 in those with parkinsonism or Lewy Body Disease 100% D13 for benign essential tremor 100% E2 if eGFR < 30 ml/min/1.73m2 100% E3 if eGFR < 15 ml/min/1.73m2 100% E4 if eGFR < 50 ml/min/1.73m2 100% E5 if eGFR < 10 ml/min/1.73m2 100% E6 if eGFR < 30 ml/min/1.73m2 100% F4 [Oral elemental iron doses greater than 200 mg daily] 100% H1 with history of peptic ulcer disease or gastrointestinal bleeding, unless with concurrent PPI or H2 antagonist 100% H5 for osteoarthritis 100% J5 without progestogen in patients with intact uterus 100%
RkJQdWJsaXNoZXIy MTk4NDMw